Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
05 07 2023
Historique:
received: 05 04 2023
accepted: 08 06 2023
medline: 31 7 2023
pubmed: 28 7 2023
entrez: 28 7 2023
Statut: epublish

Résumé

Oncological outcomes are improving in gastrointestinal cancer with advancements in systemic therapies, and there is notable potential in combining immunotherapy and radiation therapy (RT) to allow for further improvements. Various preclinical and early phase II studies have shown promising synergy with immunotherapy and RT in gastrointestinal cancer. A few recent phase III studies have shown improved survival with the addition of immunotherapy to standard treatment for gastrointestinal cancer. The timing, duration, sequencing, and integration with other anti-cancer treatments are still areas of ongoing research. We have reviewed the published and ongoing studies of the combinations of immunotherapy and RT in gastrointestinal cancers.

Identifiants

pubmed: 37504333
pii: curroncol30070473
doi: 10.3390/curroncol30070473
pmc: PMC10378032
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

6432-6446

Références

J Immunother Cancer. 2022 Nov;10(11):
pubmed: 36450386
Lancet Oncol. 2022 Mar;23(3):e105-e115
pubmed: 35240087
Lancet Gastroenterol Hepatol. 2022 May;7(5):446-454
pubmed: 35114169
Front Oncol. 2019 Jun 18;9:345
pubmed: 31275846
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Cancers (Basel). 2022 May 10;14(10):
pubmed: 35625962
J Immunol. 2012 Jul 15;189(2):558-66
pubmed: 22685313
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
Front Pharmacol. 2018 Mar 05;9:185
pubmed: 29556198
J Clin Oncol. 2015 Aug 20;33(24):2617-22
pubmed: 25964250
Oncologist. 2021 Jul;26(7):e1110-e1124
pubmed: 33893689
Lancet Oncol. 2022 May;23(5):659-670
pubmed: 35427471
Br J Cancer. 2009 Jan 27;100(2):266-73
pubmed: 19165197
Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):202-213
pubmed: 36108891
J Radiat Res. 2020 Nov 16;61(6):851-859
pubmed: 32960261
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Trends Cancer. 2022 Jan;8(1):9-20
pubmed: 34740553
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Radiol. 2017 Aug;90(1076):20170157
pubmed: 28541096
Cancer Manag Res. 2022 Aug 07;14:2357-2371
pubmed: 35967755
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
Clin Cancer Res. 2022 Jul 15;28(14):3021-3031
pubmed: 35552651
Lancet Oncol. 2017 Apr;18(4):446-453
pubmed: 28223062
Gut. 2019 Feb;68(2):335-346
pubmed: 29440463
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565
pubmed: 34030131
Clin Cancer Res. 2021 Jun 15;27(12):3351-3359
pubmed: 33504550
Front Oncol. 2020 Dec 14;10:604387
pubmed: 33381458
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Int J Mol Sci. 2014 Jan 10;15(1):927-43
pubmed: 24434638
Nat Rev Clin Oncol. 2022 Jan;19(1):37-50
pubmed: 34580473
Nat Med. 2020 Apr;26(4):566-576
pubmed: 32251400
Curr Oncol. 2022 Apr 20;29(5):2920-2927
pubmed: 35621628
Ann Surg. 2020 Sep 1;272(3):481-486
pubmed: 32740235
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
J Immunother Cancer. 2019 Aug 5;7(1):204
pubmed: 31383016
Lancet Gastroenterol Hepatol. 2021 Dec;6(12):1025-1035
pubmed: 34695377
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
J Clin Oncol. 2022 Jan 10;40(2):161-170
pubmed: 34637336
Front Oncol. 2021 Dec 07;11:798832
pubmed: 34950594
Semin Radiat Oncol. 2022 Apr;32(2):142-154
pubmed: 35307116
J Clin Oncol. 2022 Aug 20;40(24):2774-2788
pubmed: 35649196
Cancer Immunol Res. 2015 Apr;3(4):345-55
pubmed: 25527358
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Cancer Commun (Lond). 2021 Nov;41(11):1137-1151
pubmed: 34563100
Transl Gastroenterol Hepatol. 2020 Apr 05;5:21
pubmed: 32258525
Semin Radiat Oncol. 2013 Oct;23(4):273-80
pubmed: 24012341
Gut. 2023 Feb;72(2):406-407
pubmed: 35508369
J Surg Oncol. 2021 Mar;123(3):760-774
pubmed: 33595891
Lancet Oncol. 2015 Oct;16(13):e498-509
pubmed: 26433823
Cancer Biol Ther. 2021 Mar 4;22(3):175-183
pubmed: 33722163
Front Oncol. 2019 Nov 12;9:1157
pubmed: 31799176

Auteurs

Ritesh Kumar (R)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Jongmyung Kim (J)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Matthew P Deek (MP)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Mariam F Eskander (MF)

Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Prateek Gulhati (P)

Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Haejin In (H)

Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Timothy Kennedy (T)

Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Mihir M Shah (MM)

Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.

Miral S Grandhi (MS)

Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Lyudmyla Berim (L)

Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Kristen R Spencer (KR)

Department of Medicine, Perlmutter Cancer Center of NYU Langone Health and NYU Grossman School of Medicine, New York, NY 10016, USA.

Russell C Langan (RC)

Department of Surgical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Howard S Hochster (HS)

Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Patrick M Boland (PM)

Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Salma K Jabbour (SK)

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH